Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Gastric polyps and premalignant conditions

Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

Most gastric polyps and premalignant lesions are incidental, but active bleeding, symptomatic anaemia, gastric outlet obstruction, severe pain or suspected perforation after resection needs acute endoscopic or surgical assessment. A pathology report of high-grade dysplasia or a visible lesion suspicious for early cancer is not an A&E emergency when the patient is well, but it requires prompt specialist endoscopy MDT review rather than routine surveillance booking.

Synopsis

Classify gastric polyps accurately, assess the background mucosa and inherited context, remove lesions with meaningful neoplastic risk, and apply evidence-based surveillance to atrophy, intestinal metaplasia and dysplasia without over-scoping low-risk findings.

  • The clinically useful gastric polyp assessment combines surface pattern, size, site, number, histology and background mucosa; the word polyp alone does not determine risk.
  • Fundic-gland polyps are usually small, smooth and multiple in the fundus or body, often during PPI exposure, and sporadic lesions have very low malignant potential.
  • Numerous fundic-gland polyps in a young person, dysplasia within one, an antral location or concomitant duodenal adenoma should prompt assessment for familial adenomatous polyposis.
  • Hyperplastic polyps arise in an inflamed or atrophic stomach; test and eradicate H. pylori, inspect the surrounding mucosa and resect large, pedunculated, symptomatic or dysplastic lesions.
  • Gastric adenomas carry important malignant and synchronous-neoplasia risk and should be completely resected through an expert pathway with careful examination of the entire stomach.
  • Atrophy and intestinal metaplasia are premalignant fields rather than polyps; topographical biopsies establish whether disease is limited to the antrum or extends into the body.
  • BSG recommends three-yearly surveillance for extensive gastric atrophy or intestinal metaplasia affecting both antrum and body in suitable patients, with selected exceptions and shared decision-making.
  • Visible dysplasia should be staged for en-bloc endoscopic resection, while non-visible dysplasia requires expert pathology review and repeat high-quality enhanced examination to find a hidden lesion.

Key red flags

Non-visible dysplasia

Dysplasia reported from apparently flat random biopsies may reflect a subtle missed lesion or interpretive uncertainty and should trigger expert pathology confirmation plus prompt enhanced repeat endoscopy.

Early cancer morphology

Depression, spontaneous bleeding, ulceration, converging folds, irregular microvascular pattern or non-lifting raises invasive neoplasia concern and should stop casual snare removal in favour of expert staging.

Investigation priorities

01
High-definition enhanced upper-GI endoscopyFirst step

Characterise every lesion and search systematically for synchronous neoplasia.

Management branches

ClassifyDescribe lesion and field

One or more gastric polyps or a premalignant biopsy finding is identified at endoscopy.

  1. Record lesion morphology, size, number and location with photographs, and use enhanced imaging to identify depression, irregular pattern or a resection boundary.
  2. Obtain appropriate lesion tissue while sampling antrum and body background separately when hyperplastic, adenomatous, atrophic or metaplastic disease is possible.
  3. Reconcile optical diagnosis, pathology, H. pylori status, PPI exposure and family phenotype in a clear final plan rather than issuing an isolated histology result.

Key medicines

H. pylori eradication in premalignant gastric diseaseUse the current seven-day NICE and local-formulary PPI plus two-antibiotic combination, tailored to penicillin allergy, previous exposure and resistance advice, followed by a properly prepared active test of cure.Check interactions, allergy, pregnancy, QT risk and renal or hepatic impairment. Successful eradication does not cancel surveillance when the extent of atrophy, metaplasia or dysplasia independently warrants it.
Review of long-term proton-pump inhibitor exposureContinue the lowest effective licensed PPI dose only for a current indication; do not stop abruptly or solely because ordinary fundic-gland polyps are present without considering reflux, ulcer and bleeding risk.PPI-associated fundic-gland polyps rarely require surveillance. Balance rebound acid symptoms and the original indication, and remember that PPI withdrawal does not treat adenoma or extensive premalignant mucosa.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • BSG gastric adenocarcinoma risk-management guidelineUK management of fundic-gland, hyperplastic and adenomatous polyps plus atrophy, metaplasia and dysplasia surveillance.
  • BSG, AUGIS and RCPath upper-GI biopsy guidanceCurrent practical UK tissue-sampling recommendations for gastric polyps and premalignant mucosa.
  • BSG and AUGIS upper-GI endoscopy quality standardsHigh-quality inspection, imaging, lesion description and early neoplasia-recognition standards.
  • NICE CG184: H. pylori eradication guidanceNational antimicrobial selection and active-test preparation for treating the principal modifiable gastric carcinogen.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom